as 06-20-2025 4:00pm EST
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.
Founded: | 1981 | Country: | United States |
Employees: | N/A | City: | EMERYVILLE |
Market Cap: | 300.5M | IPO Year: | N/A |
Target Price: | $69.50 | AVG Volume (30 days): | 40.4K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.73 | EPS Growth: | N/A |
52 Week Low/High: | $18.35 - $35.00 | Next Earning Date: | 08-12-2025 |
Revenue: | $42,909,000 | Revenue Growth: | 638.41% |
Revenue Growth (this year): | 70.91% | Revenue Growth (next year): | 14.00% |
XOMA Breaking Stock News: Dive into XOMA Ticker-Specific Updates for Smart Investing
GlobeNewswire
4 days ago
GlobeNewswire
a month ago
Argus Research
a month ago
Simply Wall St.
a month ago
Simply Wall St.
a month ago
Zacks
a month ago
Associated Press Finance
a month ago
GlobeNewswire
a month ago
The information presented on this page, "XOMA XOMA Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.